Meyka AI API is live for developers.Start building.
Advertisement
Blueprint Medicines Corporation

Blueprint Medicines Corporation (BPMC) Stock Overview

Explore Blueprint Medicines Corporation’s financial performance, market position, analyst ratings, and future outlook.

BPMC●NASDAQ
HealthcareBiotechnology
$129.46
$0.18(0.14%)
U.S. Market is Open · 14:07
Advertisement

Blueprint Medicines Corporation (BPMC)

Meyka AI Score

Z

Key Financials

Market Cap8.4B
P/E Ratio-166.47
EPS (TTM)$-2.51
ROE-0.15%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

BPMC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Blueprint Medicines Corporation (BPMC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -166.47 and a market capitalization of 8.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
27.31%
6-Month Change
39.99%
Year-to-Date (YTD) Change
48.46%
1-Year Change
35.28%
3-Year Change
111.64%
5-Year Change
71.29%
All-Time (Max) Change
586.06%

Contact Information

https://www.blueprintmedicines.com
617 374 7580
45 Sidney Street, Cambridge, MA, 02139

Company Facts

6,820 Employees
IPO DateApr 30, 2015
CountryUS

Frequently Asked Questions